反义寡核苷酸作为抗癌治疗药物的临床开发。 - Suppr

Suppr

超能文献

Clinical development of antisense oligonucleotides as anti-cancer therapeutics.

作者信息

Chen Helen X

机构信息

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

出版信息

Methods Mol Med. 2003;75:621-36. doi: 10.1385/1-59259-324-0:621.

DOI:10.1385/1-59259-324-0:621

PMID:12407768

Abstract

摘要

相似文献

Clinical development of antisense oligonucleotides as anti-cancer therapeutics.

Methods Mol Med. 2003;75:621-36. doi: 10.1385/1-59259-324-0:621.

Antisense anticancer oligonucleotide therapeutics.

Curr Cancer Drug Targets. 2001 Nov;1(3):177-96. doi: 10.2174/1568009013334133.

Antisense oligonucleotides: the state of the art.

Curr Med Chem. 2005;12(19):2193-214. doi: 10.2174/0929867054864859.

Recent status of the antisense oligonucleotide approaches in oncology.

Fundam Clin Pharmacol. 1996;10(2):97-115. doi: 10.1111/j.1472-8206.1996.tb00153.x.

Antisense therapy.

Curr Opin Oncol. 1996 Nov;8(6):509-15. doi: 10.1097/00001622-199611000-00011.

Preclinical and clinical experience of antisense therapy for solid tumors.

Curr Opin Mol Ther. 1999 Aug;1(4):458-63.

Applications of antisense oligonucleotides in oncology.

Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):237-61.

Antisense oligonucleotides as therapeutics for malignant diseases.

Semin Oncol. 1997 Apr;24(2):187-202.

Effect of antisense inhibition of Urokinase receptor on malignancy.

Curr Top Microbiol Immunol. 1996;213 ( Pt 3):101-12. doi: 10.1007/978-3-642-80071-9_7.

Antisense oligonucleotides and the rational design of new antitumor drugs.

Rev Esp Enferm Dig. 2005 Jul;97(7):467-71. doi: 10.4321/s1130-01082005000700001.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Clinical development of antisense oligonucleotides as anti-cancer therapeutics.

Methods Mol Med. 2003;75:621-36. doi: 10.1385/1-59259-324-0:621.

Antisense anticancer oligonucleotide therapeutics.

Curr Cancer Drug Targets. 2001 Nov;1(3):177-96. doi: 10.2174/1568009013334133.

Antisense oligonucleotides: the state of the art.

Curr Med Chem. 2005;12(19):2193-214. doi: 10.2174/0929867054864859.

Recent status of the antisense oligonucleotide approaches in oncology.

Fundam Clin Pharmacol. 1996;10(2):97-115. doi: 10.1111/j.1472-8206.1996.tb00153.x.

Antisense therapy.

Curr Opin Oncol. 1996 Nov;8(6):509-15. doi: 10.1097/00001622-199611000-00011.

Preclinical and clinical experience of antisense therapy for solid tumors.

Curr Opin Mol Ther. 1999 Aug;1(4):458-63.

Applications of antisense oligonucleotides in oncology.

Cell Mol Biol (Noisy-le-grand). 1994 May;40(3):237-61.

Antisense oligonucleotides as therapeutics for malignant diseases.

Semin Oncol. 1997 Apr;24(2):187-202.

Effect of antisense inhibition of Urokinase receptor on malignancy.

Curr Top Microbiol Immunol. 1996;213 ( Pt 3):101-12. doi: 10.1007/978-3-642-80071-9_7.

Antisense oligonucleotides and the rational design of new antitumor drugs.

Rev Esp Enferm Dig. 2005 Jul;97(7):467-71. doi: 10.4321/s1130-01082005000700001.